Pinned Tweet
link.springer.com/article/10…
Our team is delighted to share our recently published article:
“Advances in Non-statin Lipid Therapies: A Narrative Review of Evolving Strategies for Cardiovascular Risk Reduction” in the American Journal of Cardiovascular Drugs.
Drawing from 138 references, we synthesized evidence, proposing frameworks and nuances to consider. Key highlights include:
✅ Practical considerations for ezetimibe, PCSK9 mabs/inclisiran, bempedoic acid, quoting pivotal trials, observational and pragmatic studies, and safety data to support these considerations
✅ Emerging therapies like CETP inhibitors, agents that target APO C-III, APO A-1, APO-B, and ANGPTL3, as well as CRISPR technology and inflammation-modulating agents. Coupled with a brief overview of lipid trafficking mechanisms to better understand these agents
✅ The concept of Residual Cardiovascular risk and how it plays into future research directions for ASCVD risk reduction, e.g Ziltivekimab etc
✅ Cost-effectiveness of these agents and integration of ICER in practical decision-making.
✅ Adherence, statin-intolerance/ drucebo effect, and patient preference challenges in real-world lipid management
This work reflects the contributions of a multi-institutional team spanning the U.S., U.K., and internationally, bringing together academic and clinical perspectives.
🔗 Access the article via Springer Nature’s SharedIt link: rdcu.be/eDdQN
We are grateful to our mentors and collaborators for making this ambitious project possible. We hope this serves as a useful resource for clinicians, researchers, and policymakers.
Three long years of growth, resilience, and perseverance. This journey has been filled with highs, lows, lessons, and unforgettable experiences. I am deeply grateful for every moment because each one shaped me and brought me to this monumental milestone.
IM residency 👨🏾🎓✅
Kayode Ogunniyi MD, MRCP(UK) retweeted
Just 250 years ago, America didn’t exist. Let that sink in.
Within three generations of people, this country has accomplished the impossible
> first country to send human to the moon
> invented the internet and core infrastructure behind it (ARPANET, TCP/IP)
> invented airplanes
> invented the telephone
> invented electricity distribution
> invented reusable rockets
> invented the polio vaccine and mRNA technology
> invented the GPS
> built the deepest capital markets in history
> won 34% of all nobel prize awards, more than the next two countries combined
> annually spend a third of the world’s entire R&D budget
> led the Genome project that sequenced human DNA
> hold just 4% of the population but contribute 25% to the world’s GDP
> hold the oldest written national constitution that still remains in force
The birth of America was not just a win for Americans. It was a win for the entire world.
God bless America. Greatest country on the planet.
Kayode Ogunniyi MD, MRCP(UK) retweeted
Exciting new option to lower #apoB #ldl #nonHdlc and Lp(a) @nationallipid @ASPCardio @CMHC_CME @society_eas @BCMHeart @Texas_Heart @BCM_CVRI @BCMFromtheLabs @BCMDeptMedicine @LaylaAbushamat @PamelaBMorris @PamTaubMD @rblument1 @DrMarthaGulati @pnatarajanmd
Among adults with HeFH who were already taking statin therapy, treatment with enlicitide was well tolerated and reduced levels of LDL-C, apolipoprotein B, non–HDL-C, and lipoprotein(a).
#AHA25 @AHAScience
ja.ma/4nQHAzM
Kayode Ogunniyi MD, MRCP(UK) retweeted
Special thanks to trainees, colleagues, collaborators and friends @yakoubenehasan @LaylaAbushamat @hwubcm @virani_md @AnumSaeedMD @AKulkarniMD Vijay Nambi RonHoogeveen @EugeniaGianos @ProfSNicholls @ProfKausikRay @BCMHeart @BCM_CVRI @nationallipid @CMHC_CME
Congratulations to @CBallantyneMD on receiving the AHA Distinguished Scientist Award! His groundbreaking work continues to shape and inspire cardiovascular medicine. lnkd.in/gVS6wzNq
hashtag#AHA2025 hashtag#Cardiology hashtag#TexasHeartatBCM hashtag#distiguishedscientist
Kayode Ogunniyi MD, MRCP(UK) retweeted
Cardiovascular disease is a leading cause of maternal complications. Telehealth, wearables & remote monitoring enable early detection and personalized care, improving outcomes and access. onlinelibrary.wiley.com/doi/…
#MaternalHealth #CardioObstetrics #DigitalHealth #HealthEquity
Kayode Ogunniyi MD, MRCP(UK) retweeted
#AHA2025 - looking forward to IL-1 Blockade in Patients With STEMI: a Pooled Analysis of Randomized Clinical Trials of Anakinra and Goflikicept | Circulation ahajournals.org/doi/abs/10.1… @UVACVRC @VCUHealthHeart @VCUPharmacy @micheleg1390 @bvantassell @PaulCremerMD @SempreRossa
Kayode Ogunniyi MD, MRCP(UK) retweeted
NEW on Heart Rhythm TV: How do GLP-1 receptor agonists impact outcomes in patients with AF? 🫀
In this episode of @CardioNerds Journal Club, Jeanne du Fay de Lavallaz, MD, and @RamyDossMD are joined by @VarunSundaram4 and @CardiacepPA to break down the landmark TRANSFORM-AF trial and what it means for AF care in obesity & diabetes. See the full interview here #EPeeps ➡️ bit.ly/4hRTWWU
Kayode Ogunniyi MD, MRCP(UK) retweeted
BREAKING: In the latest #HRStv Journal Club, @DanielAlyeshmer and @atulverma_md break down the OCEAN trial, a late-breaking clinical trial from #AHA2025 exploring anticoagulation vs. low-dose aspirin after successful atrial fibrillation ablation. See the full interview here #EPeeps ➡️ bit.ly/4nFCRAH
Kayode Ogunniyi MD, MRCP(UK) retweeted
LAAC vs best medical care
Thrombotic events - higher
Bleeding events -- higher (counting procedure; also see AVERROES)
CV death -- higher (please don't dare tell me that it was noise because if you do, let's relook at PROTECT and PREVAIL
LAAC done in experienced labs
#AHA25
Kayode Ogunniyi MD, MRCP(UK) retweeted
In my view, people don’t give APOC3 nearly as much credit as they give PCSK9. Honestly, APOC3 inhibition might end up being far more life-transforming.
Before PCSK9 inhibitors, we already had statins that revolutionized LDL-C lowering. PCSK9 added value, but its market impact was modest.
For triglycerides (TGL), though, we’ve had nothing truly effective. APOC3 inhibition changes that — its impact on TGL reduction is absolutely transformative.
When I was a medical student, I vividly recall taking care of very very sick patients with acute pancreatitis in the ICU.
Remarkable to see how APOC3 inhibition (here, olezarsen) is now shown to be a highly effective therapy for severe hypertriglyceridemia, esp among those with prior pancreatitis to reduce risk for acute pancreatitis (NNT 20 for all and 4 for those with prior) & yield remission (up to ~50%) for hypertriglyceridemia. Congrats @marstonMD @TIMIStudyGroup! nejm.org/doi/full/10.1056/NE… #AHA25 @NEJM
Kayode Ogunniyi MD, MRCP(UK) retweeted
Honored to receive this award from
@American_Heart thanks to many great mentors, collaborators and trainees @vijay_nambi @hwubcm @LaylaAbushamat @ProfKausikRay @virani_md @LizSelvin @Texas_Heart @BCMHeart @ChiadiNdumele @BCM_CVRI
BCM @bcmhouston cardiologist @CBallantyneMD named a 2025 Distinguished #Scientist by the @American_Heart Association. @BCMDeptMedicine bcm.edu/news/bcm-cardiologis…
Kayode Ogunniyi MD, MRCP(UK) retweeted
CORALreef Lipids Trial presented by Ann Marie Navar @UTSWMedCenter #AHA25
🫀 Pivotal phase 3 trial of enlicitide decanoate, a once-daily oral PCSK9 inhibitor (macrocyclic peptide), added to background lipid-lowering therapy
🫀 2:1 randomization: enlicitide 20 mg PO daily vs placebo x 52 wks
🫀 55.8% greater LDL-C reduction vs placebo at week 24
🫀 Majority of treated patients achieved both ≥50% LDL-C reduction and LDL-C <70 mg/dL; large proportion <55 mg/dL similar to injectable PCSK9i
🫀safe, effective
Now we await outcomes trials #CVPrev #LBCT #CORALreef











































